AKT1 and cancer: The expression of the MST3 gene was found to be elevated in different tumour types and was found to have a role in phosphorylating the protein AKT at the amino acid position Thr21, which causes its activation and induces PD-L1, which clears its anti-tumour immunity modulator role and thereby shows it as a promising target for immunotherapy in cancer [15].